Biotech Banter: The Realities Of Manufacturing

As the commercial market for cell and gene therapies continues to grow, there is a more pressing case for fully automated, end-to-end solutions to close processes up. However, there is still a need to demonstrate the efficacy of moving to an automated system and how to balance the need for flexibility.

This episode of Biotech Banter features Dr. David Smith, Vice President of Development at BioCentriq, and Dr. Qasim Rafiq, an Associate Professor in Cell and Gene Therapy Bioprocess Engineering at University College London. Together, they discuss the realities of manufacturing, including automated processes, the benefits and possibilities around “platformization,” the challenges associated with moving early-stage companies into a commercialization structure, and how we in the industry can support the academics developing these processes.